RxDoctor Payments Data

Stephen Broadwater, MD

Interventional Cardiology · Martinez, GANPI 1083697478

Payments from drug & device makers

$5,144in general payments, 2019–2025

Across 265 payments — averaging $19.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$898
  • AstraZeneca$421
  • Pfizer$407
  • Abbott$404
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$352
  • Amgen$304
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$4,85794%
  • Education$2876%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,144 in reported general payments places this provider in the 30th percentile of 218 interventional cardiology providers in Georgia.

See all interventional cardiology providers in Georgia

Medicare billing

Part B allowed, 2024
$75,829
Medicare patients
449
Services billed
792

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban112$138,056
XareltoRivaroxaban44$53,050
Atorvastatin Calcium185$1,981
Metoprolol Succinate91$1,968
Ranolazine ErRanolazine12$1,724
Ezetimibe42$1,306
ClopidogrelClopidogrel Bisulfate104$1,283
Enoxaparin Sodium14$1,120
Lisinopril83$810
Diltiazem 24hr Er (Cd)Diltiazem Hcl42$778
Carvedilol87$739
Rosuvastatin Calcium41$732
Amiodarone Hcl27$717
Amlodipine Besylate120$601
Nitroglycerin37$540

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$407$138,056112 claims
Johnson & JohnsonXarelto$120$53,05044 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 218 interventional cardiology providers in Georgia.

Other interventional cardiology in Martinez

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →